期刊文献+

药械警戒快讯

Pharmacovigilance News
下载PDF
导出
摘要 美国FDA警告质子泵抑制剂可能引起骨折风险 2010年5月25日,美国食品药品监督管理局(FDA)发布信息称,美国正在修订质子泵抑制剂类药品的标签和说明书,包括处方药和非处方药,加入有关该类产品可能引起髋骨、腕骨、脊骨骨折风险的警示。
出处 《中国执业药师》 CAS 2010年第9期21-22,共2页 China Licensed Pharmacist
  • 相关文献

参考文献8

  • 1Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture[J]. Calcif Tissue Int, 2006, 79(2):76-83.
  • 2Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture [J]. JAMA, 2006,296(24):2947-2953.
  • 3Targownik LE, Lix LM, Metge C J, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures [J]. CMAJ 2008,179(4):319-326.
  • 4Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors[J]. Pharmacotherapy,2008,28(8):951-959.
  • 5Corley DA, Kubo A, Zhao W, et al.Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients [J]. Gastroenterology, 2010,139(1):93-101.
  • 6Gray SL, LaCroix AZ, Larson J, et al. Proton Pump In hibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal Women [J]. Arch Intern Med.2010.170 (9):765-771.
  • 7Yu EW, Blackwell T, Ensrud KE, et al. Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults[J]. Calcif Tissue Int,2008,83(4):251-259.
  • 8Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss [J]. Gastroenterology,2010,138 (3): 896-904.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部